One fun part of launching a new company is establishing the company culture! We are proud of the culture we have built at Precede Biosciences and are excited to expand our exceptional team. As we seek to grow, we thought we could introduce you to team members and learn directly from them why they think Precede Bio is a #GreatPlacetoWork. Hear from Jonathan Beagan who joined us in September 2023 as a #Scientist on our Computational Biology & Bioinformatics team. If you would like to help expand the reach of precision medicine by providing unprecedented resolution into disease-defining biology from a simple blood test, join us: https://bit.ly/4f8Ufuv.
Precede Biosciences
Biotechnology Research
We're impacting precision medicine with a first-in-class 🩸 liquid biopsy platform
About us
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
- Website
-
https://www.precede.bio/
External link for Precede Biosciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2021
- Specialties
- biotechnology, oncology, plasma, precision medicine, genomic liquid biopsy, drug development, biology, human biology, human biology, cancer, molecular biology, machine learning, ai, artificial intelligence, genomic medicine, and target medicines
Locations
-
Primary
Get directions
Boston, MA, US
Employees at Precede Biosciences
Updates
-
Congratulations Precede Biosciences team members - Corrie Painter and Kristian Cibulskis, and co-founder and SAB member, Toni Choueiri - for finishing the Pan-Mass Challenge this weekend, helping raise more than $50M for cancer research and treatment at Dana-Farber Cancer Institute! #pmc24 https://www.pmc.org
-
-
New data published in Clinical Cancer Research represent an exciting step towards a new paradigm of diagnostic and therapeutic precision for patients with advanced lung cancer using comprehensive epigenomic profiling from a simple blood draw. Congratulations to Dr. Jacob Berchuck, senior author for the paper, to Precede Biosciences' scientific co-founders - Drs. Matt Freedman, Toni Choueiri, and Sylvan Baca, and to the team who contributed to this important work. View publication: https://bit.ly/4ckGHun #DrugDevelopment #Healthcare #Oncology #Innovation #LungCancer
-
-
Check out the latest publication from Precede Biosciences' scientific co-founders and #ScientificAdvisoryBoard members, Drs. Matt Freedman, Toni Choueiri and Sylvan Baca, published in Cell Reports highlighting the potential of comprehensive epigenomics to impact therapeutic decision-making in kidney cancer from a simple blood draw. View publication: https://bit.ly/45DN6hG #DrugDevelopment #Healthcare #Oncology #Innovation #KidneyCancer
-
Precede Biosciences is honored to announce a new member of our Scientific Advisory Board, Rick Lanman, MD. Dr. Lanman is an inspiring, highly productive serial entrepreneur who has dedicated his life to developing less invasive diagnostic procedures for patients, a mission we are squarely focused on. #ScientificAdvisoryBoard #PrecisionMedicine #LiquidBiopsy #Epigenomics #Healthcare
-
-
#Juneteenth is the oldest nationally celebrated commemoration of the ending of slavery in the United States, which came nearly 2 ½ years after the Emancipation Proclamation. Today, we observe Juneteenth as a solemn reminder of the past and as an affirmation of our shared responsibility to value, respect and support one another.
-
-
Precede Biosciences is pleased to announce the newest member of our Scientific Advisory Board, Doron Lipson. Dr. Lipson is truly a visionary leader and we look forward to benefiting from his advice and guidance as we leverage our unique and powerful platform to impact precision medicine from a simple blood test. #ScientificAdvisoryBoard
-
-
Please join us in welcoming Josephine N. Harada to the Precede Biosciences leadership team. Josephine will be spearheading corporate and business development efforts for our novel comprehensive epigenomic #LiquidBiopsy platform. Welcome to the team, Josephine! #Partnering #Leadership #BusinessDevelopment
-
-
Today is Boston's Pride celebration, a day in which our hometown celebrates the rich diversity and culture of the LGBTQ+ community. At Precede Biosciences, we strive to build a diverse and inclusive workplace that honors and values each of our team members. This Pride month, we celebrate and give a shout out to our LGBTQ+ team members, collaborators, friends, and family members.
-
-
Watch Precede Biosciences' Jonathan Beagan summarize the data on our comprehensive epigenomic #LiquidBiopsy platform's ability to predict ER IHC status and quantify ER signaling pathway activity in breast cancer patients from 1 mL of plasma. View data: https://bit.ly/4aNcZN1 #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment